Last reviewed · How we verify
Vantin (CEFPODOXIME PROXETIL)
Vantin (generic name: CEFPODOXIME PROXETIL) is a Cephalosporin Antibacterial Small molecule drug developed by Pfizer. It is currently FDA-approved (first approved 1992) for Acute Moraxella catarrhalis bronchitis, Acute bacterial bronchitis, Acute bacterial sinusitis.
Vantin, also known as cefpodoxime, is a small molecule that inhibits bacterial penicillin-binding protein. It has been studied in clinical trials for various conditions, including blistering distal dactylitis, diarrhea, and sinusitis.
At a glance
| Generic name | CEFPODOXIME PROXETIL |
|---|---|
| Sponsor | Pfizer |
| Drug class | Cephalosporin Antibacterial |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1992 |
Approved indications
- Acute Moraxella catarrhalis bronchitis
- Acute bacterial bronchitis
- Acute bacterial sinusitis
- Acute exacerbation of chronic bronchitis
- Acute gonococcal cervicitis
- Acute gonococcal urethritis
- Acute maxillary sinusitis
- Acute otitis media
- Bacterial pneumonia
- Bacterial urinary infection
- Escherichia coli urinary tract infection
- Gonorrhea
- Gonorrhea of rectum
- Haemophilus Influenzae Acute Otitis Media
- Haemophilus Influenzae Chronic Bronchitis
- Haemophilus influenzae pneumonia
- Infection due to Staphylococcus aureus
- Infection of skin AND/OR subcutaneous tissue
- Infective otitis media
- Klebsiella cystitis
Common side effects
- Diarrhea
- Diaper rash/Fungal skin rash
- Vomiting
- Nausea
- Vaginal Fungal Infections
- Vulvovaginal Infections
- Abdominal Pain
- Headache
- Other skin rashes
- Dizziness
- Syncope
- Vaginitis
Drug interactions
- cimetidine
- esomeprazole
- famotidine
- lansoprazole
- omeprazole
- rabeprazole
- ranitidine
Key clinical trials
- Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
- Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
- Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2 (NA)
- Efficacy and Safety of Modified Release Cefpodoxime Formulation in the Treatment of Acute Sinusitis. (PHASE3)
- Enhanced Versus Extended Preoperative Antibiotic Prophylaxis Regimens for Retrograde Intrarenal Surgery in High Infectious Risk Patients (PHASE3)
- Healthy Patients & Effect of Antibiotics (NA)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vantin CI brief — competitive landscape report
- Vantin updates RSS · CI watch RSS
Frequently asked questions about Vantin
What is Vantin?
What is Vantin used for?
Who makes Vantin?
What is the generic name of Vantin?
What drug class is Vantin in?
When was Vantin approved?
What development phase is Vantin in?
What are the side effects of Vantin?
Related
- Drug class: All Cephalosporin Antibacterial drugs
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Acute Moraxella catarrhalis bronchitis
- Indication: Drugs for Acute bacterial bronchitis
- Indication: Drugs for Acute bacterial sinusitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing